Acnecutan in the treatment of severe forms of acne


A new technology of production of oral isotretinoin, LIDOSE®, made it possible to increase its bioavailability by 20%,
preserve high efficiency of the drug while reducing the quantity of isotretinoin to be taken orally by 20%, and, therefore,
reduce both daily and course dose of the drug. The authors present the results of a study of clinical efficiency of
Acnecutan in treatment of patients suffering from medium to severe acne taking into account side effects. They also give
data on the administration of Acnecutan, which demonstrates the highest efficiency in treatment of this disease.


  1. Marsden J.R., Laker M.F., Ford G.P. et al. Effect of low dose cyproterone acetate on the response of acne to isotretinoin. Br J Dermatol 1984; Jun: 110 (6): 697-702.
  2. Ng C.H., Schweitzer I. The association between depression and isotretinoin use in acne. Aust N Z J Psychiatry 2003; Feb; 37 (1): 78-84.
  3. Plewig G., Hennes R., Maas B. et al. Remission behavior following low-dose 13-cis-retinoic acid in papulopustular acne. Z Hautkr 1986; Sep 1: 61 (17): 1205-10.
  4. Plewig G. Isotretinoin Therapie: Wann, was, wie? In: Fortschritte der praktischen Dermatologie und venerologie. 2004 (Hrsg. G. Plewig, P. Kaudewitz, C.A. Sander). Springer Berlin Heidelberg 2005; 245-258.
  5. Волкова Е.Н. Инновационный подход к системной терапии акне. Тезисы III Всероссийского конгресса дерматовенерологов. Казань, 2009.
  6. Адаскевич И.П. Акне: вульгарные и розовые. Н.Новгород: НГМА, 2003.
  7. Масюкова С.Л. Акне: проблема и решение. СошМед, 2002.

Copyright (c) 2011 Nazhmutdinova D.K., Takha T.V., Shvets O.I., NAZHMUTDINOVA D.K., TAKHA T.V., SHVETS O.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies